amphotericin-b and Parkinson-Disease--Secondary

Topics: Amphotericin B; Carbidopa; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myelomonocytic, Acute; Levodopa; Lung Diseases; Middle Aged; Parkinson Disease, Secondary

Topics: Adult; Amphotericin B; Brain Diseases; Female; Humans; Parkinson Disease, Secondary

A 24-year-old man with an 11-year history of i.v. drug use rapidly developed parkinsonism clinically indistinguishable from MPTP toxicity and Parkinson's disease. Although tests were negative for the human immunodeficiency virus, radiologic evaluation revealed bilateral striatal lesions. Stereotactic biopsy demonstrated septate hyphae consistent with either aspergillosis or mucormycosis. Gradual improvement followed systemic therapy with amphotericin B.

Topics: Adult; Amphotericin B; Brain Abscess; Brain Diseases; Corpus Striatum; Humans; Male; Mycoses; Parkinson Disease, Secondary; Substance Abuse, Intravenous

Little information is available regarding the in-vivo effects of amphotericin B on organs other than the kidney. The increasing use of intrathecal amphotericin B has resulted in several reports of neurotoxicity associated with the drug. Development of parkinsonism following intraventricular treatment with amphotericin B for cryptococcal meningitis in a young woman suggested a direct toxic effect on nervous tissue by amphotericin B. Although transient signs of parkinsonism have been described in a patient receiving intraventricular amphotericin B, persistent parkinsonism is an unprecedented occurrence.

Topics: Adult; Amphotericin B; Cryptococcosis; Female; Humans; Injections, Intraventricular; Meningitis; Parkinson Disease, Secondary